Protalix Exploring Options - Analyst Blog

By
A A A

Protalix BioTherapeutics, Inc. ( PLX ) recently confirmed that it has hired Citigroup, Inc. ( C ) to explore strategic options. Protalix, an Israel-based biopharmaceutical company, confirmed that Citigroup will help it review multiple product partnering, technology sharing and other strategic alternatives. The news had a positive effect on the company's shares.

The confirmation came in the wake of multiple inquiries in addition to a related report appearing in the Israeli press. However, Protalix issued no assurance that it will undertake any such strategic alternative. The company declined to throw anymore light on the event at this moment.

We note that the company focuses on the developing and commercializing recombinant therapeutic proteins expressed through ProCellEx - its proprietary plant cell based expression system.

In May 2012, it gained US approval for taliglucerase alfa for injection, as an enzyme replacement therapy for the long-term treatment of adults suffering from type 1 Gaucher disease. Pharma major Pfizer Inc. ( PFE ) is responsible for marketing Taliglucerase alfa in the US under the brand name Elelyso.

We further note that Protalix has granted Pfizer an exclusive, worldwide license to develop and commercialize the drug. However, Protalix has retained such rights, pertaining to the drug, in Israel.

We believe that the association with a big player like Pfizer is a major positive for the company. Protalix /Pfizer are looking to get the drug approved in other markets as well.

Protalix currently carries a Zacks Rank #3 (Hold). Peregrine Pharmaceuticals, Inc. ( PPHM ) is an example of a biopharma stock that is more favorably placed. It carries a Zacks Rank #1 (Strong Buy).



CITIGROUP INC (C): Free Stock Analysis Report

PFIZER INC (PFE): Free Stock Analysis Report

PROTALIX BIOTHR (PLX): Free Stock Analysis Report

PEREGRINE PHARM (PPHM): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: C , PFE , PLX , PPHM

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

74%
87%
88%
100%

Most Active by Volume

64,776,012
  • $117.60 ▼ 0.86%
53,107,118
  • $10.39 ▼ 1.05%
42,226,525
  • $17.10 ▼ 0.47%
36,916,182
  • $11.02 ▼ 0.36%
34,901,621
  • $40.75 ▼ 0.10%
31,489,542
  • $15.68 ▲ 0.06%
31,037,743
  • $75.63 ▲ 2.19%
29,604,587
  • $10.11 ▼ 0.69%
As of 11/25/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com